Results from a 20-yearlong study by Opko Health Inc. (NASDAQ:OPK) are available to the public. The study known as the Malmö Diet and Cancer was evaluating the effectiveness of its 4kscore test for prostate cancer patients. It enrolled about 11,506 healthy men between of the ages 45 and 73 and who did not have previous PSA testing and or very limited PSA testing following enrollment. The evaluation was for the period 1991-1996. The men’s blood sample was cryopreserved before being followed through to December 2014 when it was tested.
The 4Kscore test was seeking to identify aggressive prostate cancer. However, the results had 317 deaths from prostate cancer having measured the 4Kscore on 1,223 men and 3,028 controls.
The potential of the 4Kscore test result
Every year close to a million prostate biopsies are carried out in the US. Apparently, only 20% actually spot high risk prostate cancer. The number of patients detected with a serious prostate cancer is still very high despite the decrease in prostate biopsies. Nonetheless, the 4Kscore test will be very beneficial since it consists of four prostate-specific kallikrein biomarkers; Total PSA, Free PSA, Intact PSA and hK2.
The 4Kscore has proved to be very reliable in making the decision of whether or not there should be a prostate biopsy. It is a powerful test for identifying men who have or may be developing aggressive prostate cancer. Certifying the results of the study, Chairman and CEO of OPKO Health Phillip Frost says, “We believe this important study further confirms results of previously reported 4Kscore studies in the United States.”
The 4Kscore test is based on over a decade of research
Opko Health says that the test is useful in determining the probability of whether or not the patient has aggressive prostate cancer. The biomarkers utilized were as a result of an extensive research by scientists at Memorial Sloan-Kettering Cancer Center. The test cost around $1000 and will be used by more than the 2 million patients with abnormal PSA tests annually.
The 4Kscore test part of the 2017 National Comprehensive Cancer Network (NCCN) given that it adds new information to the patient-physician shared decision making discussion.